Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Porphyromonas gingivalis is a Gram-negative, anaerobic bacterium recognized as a keystone pathogen in the development of chronic periodontitis (Hajishengallis et al., 2012, Nature Reviews Microbiology). It typically resides within a complex polymicrobial biofilm alongside other Red Complex pathogens like Tannerella forsythia and Treponema denticola (Socransky et al., 1998, Journal of Clinical Periodontology). These bacteria utilize specialized virulence factors, particularly gingipain proteases, to degrade host tissues and subvert the immune system (Potempa et al., 2003, Periodontology 2000). Beyond the oral cavity, P. gingivalis has been implicated in the pathogenesis of systemic conditions such as Alzheimer's disease, where its proteases have been detected in brain tissue (Dominy et al., 2019, Science Advances). Therapeutic approaches include the use of broad-spectrum antibiotics, local antiseptics, and emerging small-molecule inhibitors like atuzaginstat designed to block specific bacterial enzymes (Cortexyme, 2021, Clinical Trial Data). Targeting these organisms is essential for managing both local periodontal destruction and the associated systemic inflammatory burden. However, the complexity of the oral microbiome presents challenges in achieving selective eradication without causing dysbiosis.
Inhibition of bacterial DNA synthesis, inhibition of cell wall synthesis, inhibition of gingipain proteases, and disruption of biofilm matrix.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Porphyromonas gingivalis and other pathogenic oral biofilm bacteria.